Graham Capital Management L.P. Buys New Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Graham Capital Management L.P. acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 18,954 shares of the biotechnology company's stock, valued at approximately $251,000. Graham Capital Management L.P. owned 0.06% of AnaptysBio as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Fairmount Funds Management LLC acquired a new stake in AnaptysBio in the 4th quarter valued at $24,050,000. Boxer Capital Management LLC bought a new position in AnaptysBio during the 4th quarter valued at $17,212,000. Vanguard Group Inc. lifted its stake in AnaptysBio by 8.4% during the 4th quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after acquiring an additional 143,584 shares in the last quarter. Ensign Peak Advisors Inc lifted its stake in AnaptysBio by 184.4% during the 4th quarter. Ensign Peak Advisors Inc now owns 215,454 shares of the biotechnology company's stock valued at $2,853,000 after acquiring an additional 139,699 shares in the last quarter. Finally, Granahan Investment Management LLC bought a new position in AnaptysBio during the 4th quarter valued at $1,404,000.

Wall Street Analyst Weigh In

ANAB has been the topic of a number of recent analyst reports. Guggenheim lifted their target price on AnaptysBio from $52.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of AnaptysBio in a research note on Thursday, May 1st. Johnson Rice restated a "buy" rating on shares of AnaptysBio in a research note on Wednesday, March 26th. Wolfe Research initiated coverage on AnaptysBio in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $25.00 price objective on the stock. Finally, HC Wainwright restated a "neutral" rating and issued a $22.00 price objective on shares of AnaptysBio in a research note on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $35.88.

AnaptysBio Trading Down 1.4%

Shares of NASDAQ ANAB traded down $0.30 during midday trading on Friday, hitting $20.44. 357,651 shares of the company's stock were exchanged, compared to its average volume of 602,268. AnaptysBio, Inc. has a 12-month low of $12.21 and a 12-month high of $41.31. The company has a market cap of $600.53 million, a price-to-earnings ratio of -3.36 and a beta of -0.20. The business's fifty day moving average price is $19.36 and its two-hundred day moving average price is $18.25.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, topping analysts' consensus estimates of ($1.30) by $0.02. The company had revenue of $27.77 million during the quarter, compared to the consensus estimate of $15.27 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. Equities analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its board has authorized a share buyback program on Monday, March 24th that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the biotechnology company to buy up to 13.1% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.